Vendor, Carlsbad, CA
Primmune Therapeutics, Inc.
UEI RCE3KW671H83, CAGE 8J8L4
1 award and $11,211,689 obligated between January 30, 2024 and April 20, 2026, 100% under full and open competition, against 1.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $11,211,689 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| HDTRA124C0014Definitive Contract, January 30, 2024, Full and Open Competition, 1 offers | Defense Threat Reduction AgencyDefense Threat Reduction Agency | Oral Broad Spectrum Antiviral TLR7 Agonist for Treatment of Lassa FeverNAICS 541715, PSC AC33 | $11,211,689 |
- Places of performance
- California
- Product and service codes
- AC33 National Defense R&D Services; Defense-Related Activities; Experimental Development
- Transactions
- 14 across 1 awards